NASDAQ:IMMX Immix Biopharma (IMMX) Stock Price, News & Analysis $1.97 -0.13 (-6.19%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$1.95▼$2.1450-Day Range$1.85▼$2.4552-Week Range$1.75▼$7.75Volume147,521 shsAverage Volume195,956 shsMarket Capitalization$52.04 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Immix Biopharma alerts: Email Address Immix Biopharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside255.3% Upside$7.00 Price TargetShort InterestHealthy3.56% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$48,962 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.64) to ($0.55) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.59 out of 5 starsMedical Sector414th out of 910 stocksPharmaceutical Preparations Industry185th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingImmix Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageImmix Biopharma has only been the subject of 1 research reports in the past 90 days.Read more about Immix Biopharma's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.56% of the float of Immix Biopharma has been sold short.Short Interest Ratio / Days to CoverImmix Biopharma has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Immix Biopharma has recently decreased by 1.69%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldImmix Biopharma does not currently pay a dividend.Dividend GrowthImmix Biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMMX. Previous Next 0.6 News and Social Media Coverage Search Interest4 people have searched for IMMX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Immix Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immix Biopharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $48,962.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders55.90% of the stock of Immix Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 11.26% of the stock of Immix Biopharma is held by institutions.Read more about Immix Biopharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Immix Biopharma are expected to grow in the coming year, from ($0.64) to ($0.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immix Biopharma is -2.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immix Biopharma is -2.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmix Biopharma has a P/B Ratio of 2.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Immix Biopharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About Immix Biopharma Stock (NASDAQ:IMMX)Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.Read More IMMX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMMX Stock News HeadlinesAugust 20, 2024 | insidertrades.comImmix Biopharma, Inc. (NASDAQ:IMMX) Director Purchases $18,600.00 in StockAugust 29, 2024 | finance.yahoo.comImmix Biopharma Independent Director Acquires 2.6% More StockSeptember 7, 2024 | Behind the Markets (Ad)⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.August 29, 2024 | finanznachrichten.deImmix Biopharma, Inc.: Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2August 28, 2024 | globenewswire.comImmix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2August 12, 2024 | msn.comIMMX Stock Earnings: Immix Biopharma Beats EPS for Q2 2024July 27, 2024 | markets.businessinsider.comBuy Rating Affirmed: NXC-201’s Promising Clinical Trials and Strategic CIRM Grant Propel Positive OutlookJuly 25, 2024 | globenewswire.comCalifornia Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)September 7, 2024 | Behind the Markets (Ad)⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.July 25, 2024 | globenewswire.comCalifornia Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)July 8, 2024 | globenewswire.comImmix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201June 17, 2024 | globenewswire.comImmix Biopharma to Present at the Stifel 2024 Cell Therapy ForumMay 23, 2024 | finance.yahoo.comImmix Biopharma Insiders Placed Bullish Bets Worth US$625.7kMay 13, 2024 | investorplace.comIMMX Stock Earnings: Immix Biopharma Beats EPS for Q1 2024May 10, 2024 | globenewswire.comImmix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral PresentationApril 29, 2024 | finanznachrichten.deImmix Biopharma, Inc.: Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple MyelomaApril 29, 2024 | globenewswire.comImmix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple MyelomaApril 18, 2024 | finance.yahoo.comImmix Biopharma, Inc. (IMMX)See More Headlines Receive IMMX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immix Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/12/2024Today9/07/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IMMX CUSIPN/A CIK1873835 Webwww.immixbio.com Phone310-651-8041FaxN/AEmployees9Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$7.00 Low Stock Price Target$7.00 Potential Upside/Downside+255.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,430,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-87.09% Return on Assets-72.07% Debt Debt-to-Equity RatioN/A Current Ratio7.00 Quick Ratio7.00 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.87 per share Price / Book2.26Miscellaneous Outstanding Shares26,414,000Free Float11,649,000Market Cap$52.04 million OptionableOptionable Beta0.17 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Ilya Rachman M.B.A. (Age 51)M.D., MBA, Ph.D., Co-Founder, CEO & Chairman Comp: $637.5kMr. Gabriel Morris B.A. (Age 37)CFO & Director Comp: $637.5kMr. Sean Senn J.D.M.B.A., M.Sc., MBA, MSc, Co-FounderDr. Vladimir P. Torchilin D.Sc. (Age 77)MSE, Ph.D., Scientific Co-Founder Mr. Ben H. Lyon J.D.Executive VP & General CounselDr. Graham Ross FFPM (Age 64)M.D., Chief Medical Officer & Head of Clinical Development Mr. Nandan Oza B.S. (Age 62)Head of Chemistry, Manufacturing & Control Dr. David MarksChief Medical Officer of Cell TherapyMr. Gerhard BauerHead of Cell Thearpy ManufacturingMore ExecutivesKey CompetitorsRAPT TherapeuticsNASDAQ:RAPTLandos BiopharmaNASDAQ:LABPBioAtlaNASDAQ:BCABSeres TherapeuticsNASDAQ:MCRBPyxis OncologyNASDAQ:PYXSView All CompetitorsInsiders & InstitutionsInvst LLCBought 27,000 shares on 8/16/2024Ownership: 0.102%Carey NgBought 10,000 shares on 8/16/2024Total: $18,600.00 ($1.86/share)XTX Topco LtdSold 34,534 shares on 8/12/2024Ownership: 0.067%Renaissance Technologies LLCSold 110,815 shares on 8/9/2024Ownership: 0.586%AIGH Capital Management LLCSold 148,320 shares on 8/7/2024Ownership: 5.326%View All Insider TransactionsView All Institutional Transactions IMMX Stock Analysis - Frequently Asked Questions How have IMMX shares performed this year? Immix Biopharma's stock was trading at $6.92 on January 1st, 2024. Since then, IMMX stock has decreased by 71.5% and is now trading at $1.97. View the best growth stocks for 2024 here. How were Immix Biopharma's earnings last quarter? Immix Biopharma, Inc. (NASDAQ:IMMX) issued its quarterly earnings results on Monday, August, 12th. The company reported ($0.15) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.06. When did Immix Biopharma IPO? Immix Biopharma (IMMX) raised $23 million in an initial public offering (IPO) on Thursday, December 16th 2021. The company issued 4,200,000 shares at a price of $5.00-$6.00 per share. Who are Immix Biopharma's major shareholders? Immix Biopharma's top institutional investors include AIGH Capital Management LLC (5.33%), Renaissance Technologies LLC (0.59%), Invst LLC (0.10%) and XTX Topco Ltd (0.07%). Insiders that own company stock include Ilya M Rachman, Sean Senn, Jason Hsu, Gabriel S Morris, Carey Ng, Helen C Adams and Magda Marquet. View institutional ownership trends. How do I buy shares of Immix Biopharma? Shares of IMMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IMMX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immix Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immix Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMMX Stock Alerts